Clinical Trial Update: Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine [Phase 2]

View source ↗

Summary

This update covers the completion of a Phase 2 trial evaluating sunitinib in metastatic pancreatic cancer that progressed after first-line gemcitabine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acinar Cell Carcinoma of the Pancreas
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 2 | Status: COMPLETED